TD Cowen analyst Ritu Baral raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $37 from $35 and keeps a Buy rating on the shares. The firm said in 4Q25 Daybue and Nuplazid had non-GAAP net sales of $110M and $189M which beat consensus as 2026 total sales were guided to $1.2-1.3B.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $26 from $25 at Morgan Stanley
- Acadia Pharmaceuticals price target lowered to $24 from $25 at Stifel
- Acadia Pharmaceuticals price target raised to $35 from $34 at Citizens
- Balancing Daybue Momentum and Nuplazid Uncertainty: Justifying a Neutral Stance on ACADIA
- ACADIA Pharmaceuticals: Accelerating Commercial Momentum and Expanded Outlook Support Raised Price Target and Buy Rating